Otonomy Inc. fka OTIC

[er111a]

OTIC 3.92 Otonomy Inc
https://finance.yahoo.com/news/otonomy-reports-positive-top-line-200410183.html

Lifetime high is $32.00
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus. Saw a 43% cure rate vs 13% placebo; Which was significantly different.
Unfortunately, there are no FDA approved drug treatments for tinnitus and existing approaches rely on coping strategies. Therefore, I am very encouraged by the treatment response observed with OTO-313 in this trial as well as the consistency of the improvement for OTO-313 responders across all four tinnitus endpoints examined in this trial, and I look forward to participating in future clinical studies.”
Projected to be a a 100+ billion dollar industry with Tinnitus affects an estimated 32 percent of the U.S. population and nearly 40% globally. With a current marker cap of 92 million there is A LOT of room for growth.